Heart failure (HF) is the leading cause of mortality worldwide, affecting approximately 26 million individuals. Early detection remains critical for effective intervention, yet conventional diagnostic methods are often time-consuming and lack sensitivity. B-type natriuretic peptide (BNP), a well-established biomarker for HF, offers a promising target for rapid and accurate diagnosis. This study presents a novel field-effect transistor (FET) biosensor based on boron/nitrogen co-doped graphene oxide (BN-GO) gel, engineered for ultrasensitive detection of BNP. The BN-GO gel serves as the active channel material in a back-gated FET configuration, enabling exceptional performance in both sensitivity and dynamic range.
The biosensor demonstrates an ultra-low limit of detection (LOD) of just 10 aM, with a linear detection range spanning over 11 orders of magnitude—from 10 aM to 1 M—representing a significant advancement over existing platforms. Detection can be achieved within only 2 minutes, far surpassing the typical timelines of traditional clinical assays. These capabilities stem from the unique electrical properties of the BN-GO gel, which exhibits charge carrier mobilities exceeding 400,000 cm² V⁻¹ s⁻¹ for holes, among the highest reported for graphene-based materials. The non-flat, curved morphology of the gel also contributes to enhanced Debye screening length, reducing ion interference in physiological environments and improving signal transduction efficiency.
Functionalization was performed directly via carboxyl and amine groups present in the BN-GO gel, eliminating the need for linker molecules and minimizing steric hindrance. Anti-BNP antibodies (50E1) were immobilized without linkers, resulting in strong, covalent attachment confirmed by shifts in the Dirac point and resistance to multiple rinsing cycles. Real-time monitoring revealed a clear, concentration-dependent shift in the Dirac voltage, with a linear correlation (R² = 0.96) between VDirac and log(CBNP), validating the sensor’s quantitative potential.HO1 Antibody Technical Information
Specificity and selectivity were rigorously evaluated. No measurable response was observed when BNP was introduced to unfunctionalized channels, confirming that electrical changes arise solely from antibody-antigen binding. Furthermore, exposure to high concentrations of K⁺, OH⁻ ions, and human epidermal growth factor receptor (HER2)—a protein associated with breast cancer—produced negligible current or Dirac point shifts, indicating minimal cross-reactivity. The device remained stable over six months, maintaining consistent performance despite minor degradation in mobility.
Compared to state-of-the-art FET biosensors for BNP detection, this BN-GO gel FET outperforms in LOD, dynamic range, and speed.IL18 Antibody supplier While most devices operate within a few orders of magnitude and require longer incubation times, this system achieves unprecedented sensitivity and breadth of detection.PMID:35078392 The results validate the BN-GO gel FET as a powerful platform for point-of-care diagnostics in heart failure management.
Future work will focus on testing the biosensor in complex biological matrices such as serum and whole blood, where real-world applicability must be demonstrated. Nonetheless, this study establishes a robust proof-of-concept for next-generation ultrasensitive biosensing using advanced nanomaterials.MedChemExpress (MCE) offers a wide range of high-quality research chemicals and biochemicals (novel life-science reagents, reference compounds and natural compounds) for scientific use. We have professionally experienced and friendly staff to meet your needs. We are a competent and trustworthy partner for your research and scientific projects.Related websites: https://www.medchemexpress.com
